Physician profile
Robert Brian Wallace
NPI 1609819952
$1,829.69
in general payments reported to CMS, 2019-2025
15 companies · $482 in 2025
The $482 reported for 2025 was more than what 76% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $44.07 · 2020: $27.39 · 2021: $235 · 2022: $330 · 2023: $226 · 2024: $485 · 2025: $482.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,193.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,193.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $292.17 | 2021-2025 | Precision7 |
| Lkc Technologies, INC. | $249.24 | 2024-2025 | |
| Sight Sciences, INC. | $221.05 | 2024-2025 | Omni Surgical System, Tearcare System |
| Johnson & Johnson Vision Care, INC. | $163.03 | 2023 | Acuvue |
| Mallinckrodt Hospital Products INC. | $142.49 | 2022-2025 | Acthar |
| Allergan, INC. | $133.80 | 2019-2022 | |
| Coopervision INC. | $100.59 | 2024 | Misight Contact Lens |
| Oyster Point Pharma, INC. | $97.35 | 2024 | Tyrvaya |
| Horizon Therapeutics Plc | $95.39 | 2021 | |
| Sun Pharmaceutical Industries INC. | $89.95 | 2022 | |
| Biotissue Holdings INC. | $84.74 | 2022 | |
| Glaukos Corporation | $62.84 | 2023 | |
| Bausch & Lomb Americas INC. | $49.09 | 2025 | Infuse |
| Carl Zeiss Meditec, INC. | $27.39 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $20.57 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Brian Wallace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.